DUAL REPLACEMENT OF LNC-MEG3 AND MIR-155 TRIGGER TUMOR SUPPRESSIVE ACTIVITY IN MULTIPLE MYELOMA

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Series Info

Experimental Hematology;Volume 88, Pages S59-S59

Orcid

Abstract

an urgent need. Recent evidence demonstrated a definitive tumor suppressor role of Long non-coding RNA maternally expressed gene 3 (MEG3) and miR-155 in Multiple Myeloma (MM), however, their biological role remains unclear. It has been demonstrated that both markers are downregulated in MM patients compared to healthy. Objectives: We aimed to investigate the biological effect of double hit replacement for both lnc-MEG3 and miR-155 in MM cells, and compare it with the effect of each biomarker separately. Methods: MM cells were transfected by MEG3 overexpression plasmid and miR-155 mimic, the miR-155 and lnc-MEG3 expression levels were measured by qRT-PCR. MTT assay was performed to assess the cell proliferation, cell cycle, and apoptosis were monitored by Flow cytometry analysis. Results: lnc-MEG3 and miR-155 were downregulated in MM cells. In- vitro overexpression of lnc-MEG3 and miR-155 suppresses cell proliferation, induce cell cycle arrest, and promote apoptosis, the effect was more prominent with upregulation of both markers than with each individual biomarker. Conclusion: the present data demonstrate that dual overexpression of lnc-MEG3 and miR-155 elicits a powerful dual tumor suppressor effect in MM cells, in spite they have different signaling pathways, thus providing a promising therapeutic strategy in MM patients.

Description

SJR 2024 1.000 Q1 H-Index 131

Citation

El-Khazragy, N., Safwat, G., & Emad, P. (2020). 3066 – DUAL REPLACEMENT OF LNC-MEG3 AND MIR-155 TRIGGER TUMOR SUPPRESSIVE ACTIVITY IN MULTIPLE MYELOMA. Experimental Hematology, 88, S59. https://doi.org/10.1016/j.exphem.2020.09.083

Endorsement

Review

Supplemented By

Referenced By